Goldman Sachs analyst Matt Dellatorre raised the firm’s price target on Teva (TEVA) to $31 from $28 and keeps a Buy rating on the shares. The recently published IRA-negotiated price for Austedo, which will go into effect in 2027, was better than expected, and management has reiterated their FY27+ guidance for the product, the analyst tells investors in a research note. Goldman sees the company as capable of long-term mid-single digit EBITDA growth, driven by both topline execution and margin expansion, and no major upcoming losses-of-exclusivity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva, Fastly, MP Materials, Lemonade, Thermo Fisher: Insider Sales Unveiled!
- Teva initiated with an Outperform at Scotiabank
- Teva sees cash flow ‘probably around’ $2.7B in 2027
- Trump Weekly: White House postpones healthcare proposal after backlash
- Trump Trade: Trump says ‘tremendous progress’ on ending Ukrainian war